- Home
- FBNC vs STOK Comparison
FBNC vs STOK Comparison
Compare FBNC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBNC | STOK |
|---|---|---|
| Founded | 1934 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBNC | STOK |
|---|---|---|
| Price | $59.36 | $30.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $62.25 | $39.20 |
| AVG Volume (30 Days) | 163.1K | ★ 475.8K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | 45.65 | ★ 92.73 |
| EPS | ★ 1.13 | N/A |
| Revenue | $67,623,000.00 | ★ $184,420,000.00 |
| Revenue This Year | $37.82 | N/A |
| Revenue Next Year | $2.30 | $77.49 |
| P/E Ratio | $51.95 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $40.01 | $9.09 |
| 52 Week High | $62.64 | $40.22 |
Technical Indicators
Market Signals| Indicator | FBNC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 44.08 |
| Support Level | $59.25 | $30.34 |
| Resistance Level | $60.04 | $35.11 |
| Average True Range (ATR) | 1.20 | 1.51 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 87.46 | 44.71 |
Price Performance
Historical ComparisonAbout FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.